Private company

Theseus Pharmaceuticals, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Our development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. Our initial focus is on developing the next generation of tyrosine kinase inhibitors, or TKIs, and is rooted in the critical role that tyrosine kinases play in the development of cancer.”40 It is headquartered in Cambridge, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge, Massachusetts1
  • Incorporated inDE2
  • Business address314 Main Street, Suite 04-200, Cambridge, Ma 021422
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$54.1M in 2022+691% since 2020
-$60.0M-$40.0M-$20.0M02020: -$6.8M-$6.8M20202021: -$27.3M-$27.3M2021+300%2022: -$54.1M-$54.1M2022+98%
Net income34-$50.6M in 2022+322% since 2020
-$60.0M-$40.0M-$20.0M02020: -$12.0M-$12.0M20202021: -$27.3M-$27.3M2021+128%2022: -$50.6M-$50.6M2022+85%
Fiscal year20192020202120222023
Research and development$6.0M3$18.3M4$35.7M4
Operating expenses$27.3M4$54.1M4
Operating income-$6.8M3-$27.3M4-$54.1M4
Net income-$12.0M3-$27.3M4-$50.6M4
Earnings per share-$21.103-$2.844-$1.314
Earnings per share (diluted)-$21.103-$2.844-$1.314
Shares (weighted, basic)9.6M shares438.5M shares4
Shares (weighted, diluted)9.6M shares438.5M shares4

Compare Theseus Pharmaceuticals, Inc. with another company

Corporate structure

Theseus Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Theseus Pharmaceuticals, Inc.

  • TANG CAPITAL PARTNERS LP Filed SC 13D/A on Theseus Pharmaceuticals, Inc., latest Feb 16, 2024 (4 filings since Nov 24, 2023)
  • Frazier Life Sciences Public Fund, L.P. Filed SC 13G/A on Theseus Pharmaceuticals, Inc., latest Feb 13, 2024 (2 filings since Jan 23, 2023)
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Theseus Pharmaceuticals, Inc., latest Dec 27, 2023 (6 filings since Oct 19, 2021)
  • Foresite Capital Fund V, L.P. Filed SC 13D/A on Theseus Pharmaceuticals, Inc., latest Nov 24, 2023 (5 filings since Oct 18, 2021)
  • FMR LLC Filed SC 13G/A on Theseus Pharmaceuticals, Inc., latest Aug 10, 2023 (5 filings since Nov 10, 2021)
  • Theseus Pharmaceuticals, Inc. Cambridge, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Theseus Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$467.0K4 Dec 31, 2022$12.0K4 Dec 31, 2021+3791.7%
Accumulated depreciation$51.0K4 Dec 31, 2022$1.0K4 Dec 31, 2021+5000.0%
Property and equipment, net$416.0K4 Dec 31, 2022$11.0K4 Dec 31, 2021+3681.8%
Operating-lease assets (leased space)$4.3M4 Dec 31, 2022$4.7M4 Sep 16, 2021−7.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$94.6M4 Dec 31, 2022$244.7M4 Dec 31, 2021−61.3%
Marketable securities, current$103.4M4 Dec 31, 2022
Marketable securities, non-current$13.8M4 Dec 31, 2022

Leadership

Who has led Theseus Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy P. Clackson2021–2023

Chair

  1. Iain D. Dukes2022

President

  1. Timothy P. Clackson2021–2023
  2. Bradford D. Dahms2024

Chief financial officer

  1. Bradford D. Dahms2021–2024
2025
Board members and other officers (10)

Timeline

  1. Feb 14, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights20
  2. Dec 22, 20238-K Entered a material agreement; Ended a material agreement; Executive or director change21
  3. Dec 4, 20238-K Executive or director change22
  4. Nov 27, 20238-K Other events23
  5. Nov 13, 20238-K Results of operations; Exit or restructuring costs; Executive or director change24
  6. Oct 31, 20238-K Ended a material agreement25
  7. Aug 10, 20238-K Results of operations26
  8. Jul 13, 20238-K Results of operations; Regulation FD disclosure; Other events27
  9. Jun 9, 20238-K Shareholder vote28
  10. May 25, 20238-K Regulation FD disclosure; Other events29
  11. May 11, 20238-K Results of operations30
  12. Mar 9, 20238-K Results of operations31
  13. Oct 6, 2021New chief executive Timothy P. Clackson becomes CEO7

Calendar

When it reported results

  1. Nov 13, 2023Reported quarterly or annual results24
  2. Aug 10, 2023Reported quarterly or annual results26
  3. Jul 13, 2023Reported quarterly or annual results27
  4. May 11, 2023Reported quarterly or annual results30
  5. Mar 9, 2023Reported quarterly or annual results31
  6. Jan 5, 2023Reported quarterly or annual results32
  7. Nov 3, 2022Reported quarterly or annual results33
  8. Aug 11, 2022Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

170 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 23 major events, 75 insider forms, 22 large holders, 41 other. The latest 20:

  1. Feb 26, 202415-12G EDGAR
  2. Feb 16, 2024SC 13D/A AMENDMENT NO. 3 EDGAR
  3. Feb 15, 2024EFFECT EDGAR
  4. Feb 14, 2024S-8 POS EDGAR
  5. Feb 14, 2024S-8 POS EDGAR
  6. Feb 14, 2024POS AM EDGAR
  7. Feb 14, 2024SC TO-T/A EDGAR
  8. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  9. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  10. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  11. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  12. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  14. Feb 14, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Feb 14, 20248-K EDGAR
  16. Feb 14, 2024SC 14D9/A EDGAR
  17. Feb 13, 2024SC 13G/A EDGAR
  18. Feb 7, 2024SC TO-T/A EDGAR
  19. Feb 7, 2024CORRESP EDGAR
  20. Feb 7, 2024SC 14D9/A EDGAR

The 170 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

29 open-market trades by officers, directors and large owners since October 2021: 29 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 17, 2023Foresite Capital Opportunity Management V, LLC10% ownerBuy700,000$2.97$2.1MForm 4
Jul 17, 2023GORDON CARL LDirectorBuy479,932$3.05$1.5MForm 4
Jul 17, 2023ORBIMED ADVISORS LLCDirectorBuy479,932$3.05$1.5MForm 4
Dec 30, 2022HAYDEN DONALD J JRDirectorBuy9,900$5.00$49.5KForm 4
Dec 29, 2022Foresite Capital Opportunity Management V, LLC10% ownerBuy500,000$5.00$2.5MForm 4
Dec 29, 2022HAYDEN DONALD J JRDirectorBuy100$5.00$500Form 4
Nov 30, 2022Dahms Bradford D.President and CFOBuy1,502$6.66$10.0KForm 4
Nov 11, 2022CLACKSON TIMOTHY PPresident and CEOBuy2,500$6.80$17.0KForm 4
Nov 7, 2022GORDON CARL LDirectorBuy192,000$5.21$1.0MForm 4
Nov 7, 2022OrbiMed Genesis GP LLCDirectorBuy192,000$5.21$1.0MForm 4
Jan 21, 2022GORDON CARL LDirectorBuy111,896$9.97$1.1MForm 4
Jan 21, 2022OrbiMed Capital GP VII LLCDirectorBuy111,896$9.97$1.1MForm 4
Jan 20, 2022GORDON CARL LDirectorBuy35,000$9.95$348.2KForm 4
Jan 20, 2022OrbiMed Capital GP VII LLCDirectorBuy35,000$9.95$348.2KForm 4
Jan 19, 2022GORDON CARL LDirectorBuy11,521$9.97$114.9KForm 4
Jan 19, 2022OrbiMed Capital GP VII LLCDirectorBuy11,521$9.97$114.9KForm 4
Jan 13, 2022GORDON CARL LDirectorBuy17,320$9.43$163.3KForm 4
Jan 13, 2022OrbiMed Capital GP VII LLCDirectorBuy17,320$9.43$163.3KForm 4
Jan 12, 2022GORDON CARL LDirectorBuy18,897$10.06$190.1KForm 4
Jan 12, 2022OrbiMed Capital GP VII LLCDirectorBuy18,897$10.06$190.1KForm 4

All 29 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Theseus Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTheseus Pharmaceuticals, Inc.1
  • CIK0001745020
  • Employer ID (EIN)83-07128061
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address314 Main Street, Suite 04-200, Cambridge, MA 021421
  • Phone(857) 400-94911
  • Shares outstanding44,230,135 as of Nov 10, 20236
  • Public float$85.6M as of Jun 30, 20224
  • On EDGAR sinceJun 29, 20181
  • Filings181 in all: 4 (58), 8-K (23), 3 (17), SC 13D/A (12), 10-Q (7), UPLOAD (6), CORRESP (5), SC 13G/A (5)1
    All 40 form types

    EFFECT (3), SC 13D (3), SC 14D9/A (3), SC TO-T/A (3), 10-K (2), D (2), DEF 14A (2), DEFA14A (2), S-8 (2), S-8 POS (2), SC 13G (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-Q (1), POS AM (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2023
    Quarterly report (10-Q) Nov 17, 2023
    Proxy statement (DEF 14A) Apr 26, 2023
    Latest 8-K (8-K) Feb 14, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40